CellCentric retweeted
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: cellcentric.com/press-releas…
CellCentric retweeted
Positive clinical data presented at #ASH23. First in class p300/CBP inhibitor treating late stage multiple myeloma. Paper 2005: cellcentric.com/wp-content/u…
CellCentric retweeted
Fantastic to see everyone last night 🌟
A special thank you to our speakers and panelists who provided key insights into the engineering biology industry.
More about our #EngBio Investment Strategy 👇
co.pulse.ly/2cpaswzoph
#VentreCapital @CellCentric @AntiverseHQ
CellCentric retweeted
Inobrodib is the new name for CCS1477, @CellCentric’s pioneering drug to treat specific cancers. It is first in class, targeting p300/CBP. See: cellcentric.com/updates/blog…
CellCentric retweeted
Latest edition is now live https://teapaw.org/t.co/DrE3us4F6J feat. @Amyris @arecor_ltd @AshtonsLegal @bangodotcom @Bicycle_tx @CellCentric @Darktrace @Hewitsons @HUMABODY @Inivata @innovateuk @Jagex @kiergroup @NorthwestBio @OneNucleus @OwlstoneMedical @Phicotx @sangerinstitut
CellCentric retweeted
CellCentric expands trials of #cancer drug into US https://teapaw.org/t.co/wI0CKmK3yy @CellCentric @ChesterfordRP
CellCentric retweeted
DIARY DATE: Next Digital Cambridge Epigenetics Club meeting is 10am BST on Monday 24th May. Professor Ryan Lister (University of Western Australia) presents his work on 'Editing the epigenome'.
abcam.com/CambridgeEpigeneti…
CellCentric retweeted
Thrilled to see this come to fruition— a potentially exciting new advance in treating metastatic prostate cancer. Honored to be part of the research team! @KimmelCancerCtr
This Post is from an account that no longer exists. Learn more
CellCentric retweeted
BIA members among companies awarded Biomedical Catalyst 2016 funding - don't forget to apply for BMC 2017 Round 1! bia.me/2jeDUY3
CellCentric retweeted
Looking fwd to giving evidence tomorrow: Parliamentary Science & Tech Select Cttee, discussing tech tran: parliament.uk/business/commi… @BIA_UK
CellCentric retweeted
British business ‘benefits massively from EU’ - BIA members join 1,200 businesses, employing 1.75M+ people in @times bia.me/28P0chs
CellCentric retweeted
Interesting summary of JQ1 BET-inhibitor R&D in Nature Outlook suppl. Covers 'open innovation' slant. nature.com/nature/journal/v5…
CellCentric retweeted
Good news that @CellCentric is expanding senior team to advance its castrate resistant prostate #cancer therapies. teapaw.org/whlwest/status/6970350…
CellCentric expands team to push forward to IND: cellcentric.com/press-releas…
CellCentric retweeted
Tensha (BET inhib) acq'd by Roche$120m upfront, $535m total. More success for lean mgmt, low overhead biotech model. tenshatherapeutics.com/pdf/1…
CellCentric retweeted
#Epigenetics discovery suggests DNA modifications more diverse than previously thought cam.ac.uk/research/news/epig… dx.doi.org/10.1038/nsmb.3145
CellCentric retweeted
Good to see Sygnature Discovery expansion news. Quality UK CROs important to the biotech economy. specificationonline.co.uk/ne… @SygnatureDiscov
CellCentric retweeted
Looking fwd to chairing the RCUK/PraxisUnico tech transfer awards 2015. Recognising those who help make innovation happen. Results 15 Sept.
CellCentric retweeted
Celgene recommits to Epizyme, adding $620M in cancer drug bonuses
$CELG $EPZM cutting costs
fiercebiotech.com/story/celg…
CellCentric retweeted
Replying to @BIA_UK
@BIA_UK Networking Breakfast with Syncona Partners & @CellCentric, hosted by @FaskenMartineau. London, 16 July events.bioindustry.org/event…
CellCentric retweeted
Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares
$EPZM #biotech
fiercebiotech.com/story/glim…






















